Somatostatin receptor therapy is administered to patients with neuroendocrine tumours who do not respond adequately to standard treatment protocols and/or who have clinical and biochemical progression. The treatment is not applied in pregnancy, lactation, renal failure, severe hepatic failure, severe heart failure.

Ga-68 DOTATATE PET/CT imaging is performed before treatment to evaluate the extent of disease and areas of involvement. If there is involvement on imaging and complete blood count, liver and kidney function tests are within the appropriate range for treatment, treatment is planned.

For each patient, 4 treatment doses are planned with 4-6 week intervals. If you are receiving long-acting octreotide (Sandostatin or Somatuline) treatment, your appointment for somatostatin receptor treatment will be scheduled no earlier than 3 weeks after the long-acting octreotide injection. Your treatment is administered by slow injection of the radiopharmaceutical into a vein. Very rarely there may be temporary side effects following the injection, such as redness of the face or mild nausea.

A full body scan is performed on the 1st day after treatment. Since liver and kidney dysfunction and bone marrow suppression may develop due to treatment, complete blood count, liver and kidney function tests should be performed at the 3rd week after treatment.